Correlations between the hollow fiber model of tuberculosis and therapeutic events in tuberculosis patients: Learn and confirm

Clinical Infectious Diseases

Volumn 61, Issue , 2015, Pages S18-S24

  Gumbo, Tawanda ^a,b   Pasipanodya, Jotam G ^a   Nuermberger, Eric ^c   Romero, Klaus ^d   Hanna, Debra ^d  

^a BAYLOR RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CRITICAL PATH INSTITUTE   (United States)

Author keywords

Clinical correlations; Dose ranging; Dose scheduling; Pharmacokinetics pharmacodynamics; Resistance emergence

Indexed keywords

CIPROFLOXACIN; ETHAMBUTOL; ISONIAZID; ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; LINEZOLID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CORRELATION ANALYSIS; DRUG EFFICACY; HOLLOW FIBER MODEL OF TUBERCULOSIS; HUMAN; LUNG TUBERCULOSIS; META ANALYSIS (TOPIC); MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MONTE CARLO METHOD; NONBIOLOGICAL MODEL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN; SYSTEMATIC REVIEW; BIOLOGICAL MODEL; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DOSE RESPONSE; DRUG DEVELOPMENT; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MYCOBACTERIUM TUBERCULOSIS; TIME FACTOR; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; TIME FACTORS; TUBERCULOSIS;

EID: 84942111105     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ426     Document Type: Article

References (57)

1. Smith GC, Pell JP. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ 2003; 327:1459-61.
2. Gumbo T, Lenaerts AJ, Hanna D, Romero K, Nuermberger E. Non-clinical models for antituberculosis drug development: a landscape analysis. J Infect Dis 2015; 211(suppl 3):S83-95.
3. Pasipanodya J, Gumbo T. An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future. Antimicrob Agents Chemother 2011; 55:24-34.
4. Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007; 44:79-86.
5. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26:1-10.
6. Gumbo T, Angulo-Barturen I, Ferrer-Bazaga S. Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia. J Infect Dis 2015; 211(suppl 3):S96-106.
7. Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharmacol Ther 1997; 61:275-91.
8. Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004; 190:1642-51.
9. Gumbo T, Siyambalapitiyage Dona CS, Meek C, Leff R. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother 2009; 53:3197-204.
10. Pasipanodya JG, Nuermberger E, Romero K, Hanna D, Gumbo T. Systematic analysis of hollow fiber model of tuberculosis experiments. Clin Infect Dis 2015; 61(suppl 1):S10-7.
11. Lehmann J. Para-aminosalicylic acid in the treatment of tuberculosis. Lancet 1946; 1:15.
12. Schatz A, Bugie E, Waksman SA. Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria. Proc Soc Exper Biol Med 1944; 55:66-9.
13. Waksman SA. Standardization of streptomycin. Science 1945; 102:40-1.
14. Smith DG, Waksman SA. Tuberculostatic and tuberculocidal properties of streptomycin. J Bacteriol 1947; 54:253-61.
15. Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011; 64:401-6.
16. The Periodic Health Examination. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J 1979; 121:1193-254.
17. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339:b2535.
18. Sirgel FA, Donald PR, Odhiambo J, et al. A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother 2000; 45:859-70.
19. Donald PR, Sirgel FA, Botha FJ, et al. The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am J Respir Crit Care Med 1997; 156(3 pt 1):895-900.
20. Yeager RL, Munroe WG, Dessau FI. Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis. Am Rev Tuberc 1952; 65:523-46.
21. Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980; 121:939-49.
22. Jindani A, Dore CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 2003; 167:1348-54.
23. Devadatta S, Bhatia AL, Andrews RH, et al. Response of patients infected with isoniazid-resistant tubercle bacilli to treatment with isoniazid plus PAS or isoniazid alone. Bull World Health Organ 1961; 25:807-29.
24. Gangadharam PR, Devadatta S, Fox W, Nair CN, Selkon JB. Rate of inactivation of isoniazid in south Indian patients with pulmonary tuberculosis. 3. Serum concentrations of isoniazid produced by three regimens of isoniazid alone and one of isoniazid plus PAS. Bull World Health Organ 1961; 25:793-806.
25. Gangadharam PR, Bhatia AL, Radhakrishna S, Selkon JB. Rate of inactivation of isoniazid in south Indian patients with pulmonary tuberculosis. Bull World Health Organ 1961; 25:765-77.
26. Selkon JB, Devadatta S, Kulkarni KG, et al. The emergence of isoniazid-resistant cultures in patients with pulmonary tuberculosis during treatment with isoniazid alone or isoniazid plus PAS. Bull World Health Organ 1964; 31:273-94.
27. Selkon JB, Fox W, Gangadharam PR, Ramachandran K, Ramakrishnan CV, Velu S. Rate of inactivation of isoniazid in south Indian patients with pulmonary tuberculosis. 2. Clinical implications in the treatment of pulmonary tuberculosis with isoniazid either alone or in combination with PAS. Bull World Health Organ 1961; 25:779-92.
28. Anonymous. A comparative study of daily followed by twice- or once-weekly regimens of ethambutol and rifampicin in the retreatment of patients with pulmonary tuberculosis: second report. Tubercle 1976; 57:105-13.
29. Anonymous. Ethambutol plus isoniazid for the treatment of pulmonary tuberculosis - a controlled trial of four regimens. Tubercle 1981; 62:13-29.
30. British Medical Research Council. A controlled comparison of four regimens of streptomycin plus pyrazinamide in the retreatment of pulmonary tuberculosis. Tubercle 1969; 50:81-114.
31. Ginsburg AS, Woolwine SC, Hooper N, et al. The rapid development of fluoroquinolone resistance in M. tuberculosis. N Engl J Med 2003; 349:1977-8.
32. Hesseling AC, Walzl G, Enarson DA, et al. Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients. Int J Tuberc Lung Dis 2010; 14:560-70.
33. Visser ME, Grewal HM, Swart EC, et al. The effect of vitamin A and zinc supplementation on treatment outcomes in pulmonary tuberculosis: a randomized controlled trial. Am J Clin Nutr 2011; 93:93-100.
34. Sirgel FA, Botha FJ, Parkin DP, et al. The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 1997; 156(3 pt 1):901-5.
35. Gumbo T, Louie A, Liu W, et al. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J Infect Dis 2007; 195:194-201.
36. Gumbo T, Louie A, Liu W, et al. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob Agents Chemother 2007; 51:2329-36.
37. Gumbo T, Louie A, Deziel MR, Drusano GL. Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance. Antimicrob Agents Chemother 2005; 49:3178-81.
38. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 2011; 204:1951-9.
39. Gumbo T, Louie A, Deziel MR, et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007; 51:3781-8.
40. Srivastava S, Musuka S, Sherman C, Meek C, Leff R, Gumbo T. Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J Infect Dis 2010; 201:1225-31.
41. Ginsburg AS, Hooper N, Parrish N, et al. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis 2003; 37:1448-52.
42. Wallis RS, Palaci M, Eisenach K. Persistence, not resistance, is the cause of loss of isoniazid effect. J Infect Dis 2007; 195:1870-1.
43. Mitchison DA, Jindani A, Davies GR, Sirgel F. Isoniazid activity is terminated by bacterial persistence. J Infect Dis 2007; 195:1871-2.
44. Schmalstieg AM, Srivastava S, Belkaya S, et al. The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance. Antimicrob Agents Chemother 2012; 56:4806-15.
45. Chigutsa E, Pasipanodya JG, Visser ME, et al. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. Antimicrob Agents Chemother 2015; 59:38-45.
46. Dheda K, Gumbo T, Gandhi NR, et al. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir Med 2014; 2:321-38.
47. Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 2013; 208:1464-73.
48. Pasipanodya JG, Gumbo T. A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients. Clin Infect Dis 2013; 57:21-31.
49. Pasipanodya JG, Srivastava S, Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis 2012; 55:169-77.
50. Prahl JB, Johansen IS, Cohen AS, Fridmodt-Moller N, Andresen AB. Clinical significance of 2 h plasma concentrations of first-line antituberculosis drugs: a prospective observational study. J Antimicrob Chemother 2014; 69:2841-7.
51. Garcia-Prats AJ, Willemse M, Seifart HI, et al. Acquired drug resistance during inadequate therapy in a young child with tuberculosis. Pediatr Infect Dis J 2014; 33:883-5.
52. Chideya S, Winston CA, Peloquin CA, et al. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis 2009; 48:1685-94.
53. Weiner M, Benator D, Burman W, et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 2005; 40:1481-91.
54. Adams KN, Takaki K, Connolly LE, et al. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell 2011; 145:39-53.
55. Gumbo T. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrob Agents Chemother 2010; 54:1484-91.
56. Gumbo T, Pasipanodya JG, Wash P, Burger A, McIlleron H. Redefining multidrug-resistant tuberculosis based on clinical response to combination therapy. Antimicrob Agents Chemother 2014; 58:6111-5.
57. Gumbo T, Jotam G, Pasipanodya JG, Nuermberger E, Romero K, Hanna D. Forecasting accuracy of the hollow fiber system model of tuberculosis for clinical therapeutic outcomes. Clin Infect Dis 2015; 61(suppl 1):S25-31.